Chief Executives
Samsung Biologics CEO focuses on global business
John Rim manages Samsung Biologics' Global Sales Center for overseas expansion of contract development and manufacturing of biopharmaceuticals
By Jan 26, 2023 (Gmt+09:00)
1
Min read
Most Read
S.Korea's LS Materials set to boost earnings ahead of IPO process
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Macquarie eyes its 1st Korean data center valued around $722 mn
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Galaxy Ring, new foldables set to steal the show at Samsung Unpacked Paris
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
SK Inc. in talks to sell Pharmteco’s US CDMO plant to Novo Nordisk
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
POSCO gears up for carbon-free steelmaking with hydrogen
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
![Samsung Biologics CEO focuses on global business](https://www.kedglobal.com/data/ked/image/2023/01/26/ked202301260007.598x.0.jpg)
John Rim, chief executive of Samsung BioLogics will directly lead his company's global sales operations for biopharmaceuticals through contract development and manufacturing. The section serving the company's contract development organization (CDO) affairs also received an upgrade to focus on business expansion.
Industry sources on Wednesday said Rim decided to concurrently lead global sales operations in addition to serving as CEO, succeeding in the position James Park, a former executive at Bristol-Myers Squibb who suddenly left Samsung Biologics late last year. For the CEO of a Samsung Group affiliate to concurrently hold another position is unprecedented.
"The CEO manages a large multinational pharmaceutical company, so a positive effect is expected (from his concurrent position)," a Samsung Biologics source said.
The section serving the CDO was also upgraded from "CDO manager" to "center." The company usually employs a vice president-level executive for the job, as the first head of its CDO Development Center was Samsung Biologics Vice President Kang Ja-hoon, formerly executive director of Hanmi Pharmaceutical and the global pharmaceutical giant Novartis.
Write to Jae-Young Han at jyhan@hankyung.com
More to Read
-
-
Bio & PharmaSamsung Biologics in CDO deal talks with global pharma firm
Nov 07, 2022 (Gmt+09:00)
2 Min read -
Bio & PharmaKorea's Samsung Biologics signs $296 mn CMO deal with GSK
Oct 21, 2022 (Gmt+09:00)
1 Min read -
Bio & PharmaSamsung Biologics signs $81 mn CMO deal with Novartis
Jun 07, 2022 (Gmt+09:00)
1 Min read
Comment 0
LOG IN